Huiyu Pharmaceuticals (688553.SH): Injection HY07121 for drug clinical trial obtains approval notice.

Huiyu Pharmaceutical (688553.SH) announced recently that its wholly-owned subsidiary, Sichuan Huiyu Haiyue Pharmaceutical Technology Co., Ltd. (referred to as "Huiyu Haiyue"), has received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration for the clinical trial of the injectable drug HY07121 (project research and development code "HY-0007") for the treatment of advanced solid tumors. The injectable drug HY07121 is an anti-PD-1, anti-TIGIT, IL-15/IL-15R bispecific fusion protein independently developed by Huiyu Haiyue, a wholly-owned subsidiary of the company. Its registration classification is a Class 1 innovative therapeutic biological product. As of the disclosure date of the announcement, there are no similar products approved for market both domestically and internationally.